New drug shows promise for rare hormone disorder in early trial
NCT ID NCT03257462
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This study tested a new medicine called SPR001 in 24 adults with classic congenital adrenal hyperplasia (CAH), a genetic condition that disrupts hormone production. The goal was to see if the drug is safe and can help control the disease by lowering certain hormone levels. Participants received multiple doses of SPR001, and researchers monitored side effects and changes in key hormones like 17-hydroxyprogesterone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Spruce Biosciences Clinical Site
Orange, California, 92123, United States
-
Spruce Biosciences Clinical Site
San Diego, California, 92123, United States
-
Spruce Biosciences Clinical Site
Melbourne, Florida, 32935, United States
-
Spruce Biosciences Clinical Site
Atlanta, Georgia, 30046, United States
-
Spruce Biosciences Clinical Site
Indianapolis, Indiana, 46202, United States
-
Spruce Biosciences Clinical Site
Ann Arbor, Michigan, 48109, United States
-
Spruce Biosciences Clinical Site
Minneapolis, Minnesota, 55414, United States
-
Spruce Biosciences Clinical Site
Las Vegas, Nevada, 89148, United States
-
Spruce Biosciences Clinical Site
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.